EAST RUTHERFORD, N.J., June 3 /PRNewswire-FirstCall/ -- Cambrex
Corporation (NYSE: CBM), a leading provider to the healthcare industry, is
pleased to announce that David R. Bethune was elected to the Cambrex Board of
Directors on June 2, 2005.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
"David's vast healthcare experience and insights into the pharmaceutical
industry will be an invaluable asset to Cambrex and its Board of Directors as
we transition the business to specialty pharmaceuticals," commented James A.
Mack, Cambrex Chairman of the Board of Directors.
David R. Bethune most recently was Chairman and Chief Executive Officer of
Atrix Laboratories, a drug delivery and product development company, where he
has been a director of the company for the past ten years. Prior to Atrix
Laboratories, he was President and Chief Operating Officer of IVAX
Corporation, a pharmaceutical company. Before joining IVAX, Mr. Bethune began
a start-up pharmaceutical company venture formed by Mayo Medical Ventures, a
business unit of Mayo Clinics of Rochester.
Mr. Bethune previously served as group vice president of American Cyanamid
Company and a member of the Executive Committee where he had executive
authority for human biologicals, consumer health products, pharmaceuticals and
ophthalmics as well as global medical research. He was also President of the
Lederle Laboratories Division of American Cyanamid Company.
Mr. Bethune received a B.A. degree in accounting and economics from
Lenior-Rhyne College, Hickory, North Carolina and Masters in Business
Administration in the Executive Program from Columbia University Graduate
School.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
1900 worldwide. For more information, please visit http://www.cambrex.com.
Since the mid-1990's, Cambrex has helped customers develop their active
pharmaceutical ingredients (APIs) more efficiently and cost-effectively. The
Company has diagnosed and overcome problems that clients had in their
manufacturing processes, provided clinical or commercial quantities of
hundreds of pharmaceutical products and provided the analytical, regulatory
and other support services that clients need to shorten the time to market.
More recently, the Company expanded into the product commercialization arena
with sales and marketing services. The combined strength of experience,
breadth of products and services and success integrating over twenty
acquisitions supports the Company's strategy to move into the specialty
therapeutics market.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Anne-Marie Hess, Director, Investor Relations
& Corporate Communications of Cambrex Corporation,
+1-201-804-3062, annemarie.hess@cambrex.com
|
